220 related articles for article (PubMed ID: 25079808)
1. Targeting thrombin: an inflammatory neurotoxin in Alzheimer's disease.
Grammas P; Martinez JM
J Alzheimers Dis; 2014; 42 Suppl 4():S537-44. PubMed ID: 25079808
[TBL] [Abstract][Full Text] [Related]
2. A new paradigm for the treatment of Alzheimer's disease: targeting vascular activation.
Grammas P; Martinez J; Sanchez A; Yin X; Riley J; Gay D; Desobry K; Tripathy D; Luo J; Evola M; Young A
J Alzheimers Dis; 2014; 40(3):619-30. PubMed ID: 24503617
[TBL] [Abstract][Full Text] [Related]
3. Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.
Iannucci J; Renehan W; Grammas P
Front Neurosci; 2020; 14():762. PubMed ID: 32792902
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.
Grossmann K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946588
[TBL] [Abstract][Full Text] [Related]
5. Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
Vittal Rao H; Bihaqi SW; Iannucci J; Sen A; Grammas P
J Alzheimers Dis; 2021; 79(1):211-224. PubMed ID: 33252072
[TBL] [Abstract][Full Text] [Related]
6. Thrombin, a Key Driver of Pathological Inflammation in the Brain.
Iannucci J; Grammas P
Cells; 2023 Apr; 12(9):. PubMed ID: 37174621
[TBL] [Abstract][Full Text] [Related]
7. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
8. Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.
Manukhina EB; Downey HF; Shi X; Mallet RT
Exp Biol Med (Maywood); 2016 Jun; 241(12):1351-63. PubMed ID: 27190276
[TBL] [Abstract][Full Text] [Related]
9. The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease.
Pimentel-Coelho PM; Rivest S
Eur J Neurosci; 2012 Jun; 35(12):1917-37. PubMed ID: 22708603
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective.
Luo J; Grammas P
J Alzheimers Dis; 2010; 21(3):887-96. PubMed ID: 20634595
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S; Rauk A
Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
[TBL] [Abstract][Full Text] [Related]
13. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease.
Guzmán-Ramos K; Moreno-Castilla P; Castro-Cruz M; McGaugh JL; Martínez-Coria H; LaFerla FM; Bermúdez-Rattoni F
Learn Mem; 2012 Sep; 19(10):453-60. PubMed ID: 22984283
[TBL] [Abstract][Full Text] [Related]
14. Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.
Rami BK
Am J Alzheimers Dis Other Demen; 2012 Dec; 27(8):564-7. PubMed ID: 23144146
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.
Dragicevic N; Mamcarz M; Zhu Y; Buzzeo R; Tan J; Arendash GW; Bradshaw PC
J Alzheimers Dis; 2010; 20 Suppl 2():S535-50. PubMed ID: 20463404
[TBL] [Abstract][Full Text] [Related]
16. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
17. Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia.
Tripathy D; Sanchez A; Yin X; Luo J; Martinez J; Grammas P
Front Aging Neurosci; 2013; 5():19. PubMed ID: 23675346
[TBL] [Abstract][Full Text] [Related]
18. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis.
Grammas P; Samany PG; Thirumangalakudi L
J Alzheimers Dis; 2006 Mar; 9(1):51-8. PubMed ID: 16627934
[TBL] [Abstract][Full Text] [Related]
19. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease.
Yin X; Wright J; Wall T; Grammas P
Am J Pathol; 2010 Apr; 176(4):1600-6. PubMed ID: 20150433
[TBL] [Abstract][Full Text] [Related]
20. Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model.
Van Dam D; Coen K; De Deyn PP
J Psychopharmacol; 2010 Mar; 24(3):383-8. PubMed ID: 18957478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
